Digital Display Labels in Clinical Trials — From Concept to Practice
Complimentary
Learning Level: Intermediate
Time: 1100 - 1200 ET
Session Length: 1 hour
Traditional paper labeling in clinical trials has long constrained agility across the clinical supply chain due to limited content capacity, static information, long lead times, and the need for manual relabeling when study parameters change. As trials become increasingly complex—spanning multiple countries, languages, and adaptive study designs—these limitations introduce operational inefficiencies, waste, and risks to timely study start-up. Digital Display Labeling (DDL) represents a paradigm shift by transforming the label from a static artifact into a reusable, updateable digital platform while maintaining full regulatory compliance.
This presentation builds on the work described in the Pharmaceutical Engineering manuscript “Digital Display Labels in Clinical Trials — From Concept to Practice” (Manuscript ID 2026‑-011‑PE‑Feb) and documents the industry’s progression from early DDL concepts to clinically deployed, GMP-ready solutions. It summarizes the journey undertaken by the multi-company Digital Display Labeling Community of Practice (DDL CoP), highlighting achieved minimum viable product (MVP) configurations across vials, bottles, blisters, and cartons; human-factors studies validating usability and legibility; and end-to-end clinical pilots demonstrating operational feasibility and value.
The presentation will discuss the technical and operational foundations required to enable DDLs in real clinical settings, including hardware qualification, software validation, and ERP/MES (SAP) integration. Real-world pilot outcomes—such as cycle‑time reductions, improved user experience, and successful expiry date updates without physical relabeling—will be shared alongside key learnings related to ergonomics, scalability, and quality/regulatory engagement.
The intended outcome is to provide clinical supply, quality, regulatory, and technology leaders with a pragmatic, evidence-based blueprint for adopting DDLs at scale. By translating industry learnings into reusable frameworks, qualification approaches, and KPIs, this presentation aims to accelerate alignment across sponsors, vendors, CMOs, and regulators—positioning Digital Display Labeling as a viable, future-ready standard for modern clinical trials.
Learning Objective
- Understand how Digital Display Labeling (DDL) overcomes the limitations of traditional paper labels and enables greater agility, compliance, and efficiency in increasingly complex clinical trial supply chains.
- Learn what it takes to move DDL from concept to clinical practice, including key requirements for hardware qualification, software validation, ERP/MES integration, human factors acceptance, and regulatory readiness.
- Take away a practical, evidence-based blueprint for scaled adoption, grounded in real pilot data, cross-industry collaboration, and governance models that support future-ready clinical labeling solutions.
